Pankit Vachhani, MD

The field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.

Closing out their discussion on the management of myeloproliferative neoplasms, Rami S. Komrokji, MD, and Pankit Vachhani, MD, look toward the future treatment paradigm.

Key opinion leaders provide a comprehensive review of agents under investigation, alone or in combination, in patients with myelofibrosis.

Focusing on real-world management of myelofibrosis, experts share insight on how they would select and sequence therapies within the current paradigm.

A review of the treatment armamentarium for patients with myelofibrosis in the context of clinical trial data supporting use of these agents.

Shifting their attention to myelofibrosis, Rami S. Komrokji, MD, and Pankit Vachhani, MD, define differences between various subsets of disease.

Before closing out their review of polycythemia vera management, expert hematologist-oncologists highlight novel therapies in the pipeline.

Considerations for the selection of optimal therapy in patients with polycythemia vera, and how these novel agents may be sequenced in the event of disease progression.

Centering discussion on polycythemia vera, Rami S. Komrokji, MD, and Pankit Vachhani, MD, share an in-depth review of cornerstone therapies in this setting.

Expert hematologist-oncologists share insight on the pathways driving myeloproliferative neoplasms and biomarkers that may be targeted with novel therapy.

Broad perspective on diagnosis of the myeloproliferative neoplasms via optimal workup and molecular testing.

A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.